Corporate Overview of Bide Pharmatech (688073.SS)
Bide Pharmatech Co. Ltd., headquartered in Shanghai, remains a focal point for investors following a notably flat trading day. As of 07:33 AM Central Europe on Wednesday, 21 November 2026, the share price held steady at CNY 61.21, resulting in a 0 % change over the preceding 24 hours.
Market Fundamentals
- Current Market Capitalisation: CNY 5.2 billion
- Total Shares Outstanding: 85.7 million
- Volume Traded in the Last 24 Hours: Approximately CNY 255.9 million
- 52‑Week High / Low: CNY 88.88 (13 August 2026) / CNY 43.21 (22 June 2026)
- 200‑Day Simple Moving Average: CNY 58.29
Despite the recent stability, the stock has experienced a significant decline of 15.94 % since the end of the previous month, signalling a broader market correction or sector‑specific headwinds that investors should scrutinise.
Comparative Performance with Peer Stocks
To contextualise Bide Pharmatech’s position, the following peer companies were examined for their 24‑hour performance:
| Company | Ticker | 24‑Hour Movement | Current Price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|---|
| Shanghai Sk Automation Tec | 688155.SS | Flat (0 %) | CNY 45.76 | CNY 6.2 bn | 15.2 |
| Motic Xiamen Electric‑Grou | 300341.SZ | Flat (0 %) | CNY 12.33 | CNY 6.2 bn | 32.84 |
| Cisen Pharmaceutical Lt | 603367.SS | Flat (0 %) | CNY 13.91 | CNY 6.2 bn | 13.9 |
| Bohai Automative | 600960.SS | Flat (0 %) | CNY 3.81 | CNY 6.2 bn | – |
| Telink Semiconductor Shang | 688591.SS | Flat (0 %) | CNY 29.45 | CNY 6.2 bn | 50.66 |
While all listed peers exhibited a flat performance over the same period, their valuation metrics diverge markedly. Notably, Telink Semiconductor Shang trades at a markedly high P/E of 50.66, suggesting market expectations of robust growth, whereas Bide Pharmatech’s P/E is not disclosed here but can be inferred to be moderate given its trading price relative to its 200‑day SMA and 52‑week range.
Narrative Insight
The day‑to‑day equilibrium in Bide Pharmatech’s share price, coupled with the broader decline in its valuation over the month, paints a picture of a company that is maintaining liquidity while navigating a volatile sector. The 200‑day moving average, standing just below the current price, indicates that the stock is hovering near a critical support level; any sustained breach could accelerate the downward trend.
In contrast, peer companies display a spectrum of valuation dynamics. Shanghai Sk Automation Tec’s modest P/E of 15.2 signals a balanced risk‑return profile, while Telink Semiconductor Shang’s high multiple may reflect speculative optimism. Motic Xiamen Electric‑Grou and Cisen Pharmaceutical Lt sit in the middle of this range, suggesting moderate confidence from the market.
For investors, the flat trading day offers a window to reassess Bide Pharmatech’s strategic initiatives and operational performance, especially in the context of its peer group’s valuation benchmarks. Monitoring the stock’s proximity to its 200‑day SMA and 52‑week extremes will be essential for forecasting future movement and for making informed investment decisions.
The information herein is sourced from real‑time market data available as of the stated time and reflects the latest available figures for Bide Pharmatech Co. Ltd. and its selected peers.
